Pharmaceuticals, Biotechnology & Life Sciences

Vanda Pharma’s FDA rare pediatric designation for VCA‑894A offers new hope for Charcot‑Marie‑Tooth type 2S patients, positioning the biotech firm for breakthrough CNS therapy.

Amarin Corporation PLC, a leading biotech firm on the Frankfurt Stock Exchange, focuses on innovative cardiovascular therapeutics, driving patient outcomes and industry growth.

Outlook Therapeutics: exploring the future of cost‑effective biosimilar monoclonal antibodies in immunology and oncology – a biotech company poised to reshape treatment options and investor outlook.

Explore Purple Biotech’s breakthrough combo drugs tackling osteoarthritis pain and hypertension—India‑based, Tel Aviv‑listed, and poised to reshape chronic care.

Satellos Bioscience’s SAT‑3247 shows early muscle‑fat reduction, strength gains, and low toxicity in a six‑month DMD interim study—hinting at a new hope for adults.

Chemomab merges with Scipher for $150 M, turning its rheumatoid arthritis drug Nebokitug into a phase‑2 trial powered by AI analytics.

Suven Life Sciences adds a Singapore subsidiary, reshapes its board and converts warrants to equity—boosting global reach, governance, and capital for its CNS drug pipeline.

Discover how Eli Lilly’s GLP‑1 drugs drove the company past $1 trillion, sparking new Asia expansion and a bullish future for pharma.

Avant Brands Inc. showcases Canada’s premium handcrafted cannabis market, balancing volatility with strategic growth, and poised to shape the industry’s future.

Agios Pharmaceuticals tackles cancer metabolism—targeting glycolysis, fatty acid metabolism and autophagy to pioneer breakthrough therapies that could reshape cancer treatment.